- Home
- URGN vs SAGE Comparison
URGN vs SAGE Comparison
Compare URGN & SAGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- SAGE
- Stock Information
- Founded
- URGN 2004
- SAGE 2010
- Country
- URGN United States
- SAGE United States
- Employees
- URGN N/A
- SAGE N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- SAGE Biotechnology: Pharmaceutical Preparations
- Sector
- URGN Health Care
- SAGE Health Care
- Exchange
- URGN Nasdaq
- SAGE Nasdaq
- Market Cap
- URGN 547.1M
- SAGE 462.2M
- IPO Year
- URGN 2017
- SAGE 2014
- Fundamental
- Price
- URGN $11.33
- SAGE $5.27
- Analyst Decision
- URGN Strong Buy
- SAGE Hold
- Analyst Count
- URGN 5
- SAGE 19
- Target Price
- URGN $44.50
- SAGE $11.53
- AVG Volume (30 Days)
- URGN 351.4K
- SAGE 944.7K
- Earning Date
- URGN 11-06-2024
- SAGE 10-29-2024
- Dividend Yield
- URGN N/A
- SAGE N/A
- EPS Growth
- URGN N/A
- SAGE N/A
- EPS
- URGN N/A
- SAGE N/A
- Revenue
- URGN $89,363,000.00
- SAGE $106,399,000.00
- Revenue This Year
- URGN $13.39
- SAGE N/A
- Revenue Next Year
- URGN $45.06
- SAGE $122.78
- P/E Ratio
- URGN N/A
- SAGE N/A
- Revenue Growth
- URGN 15.64
- SAGE 837.60
- 52 Week Low
- URGN $10.60
- SAGE $4.62
- 52 Week High
- URGN $20.70
- SAGE $28.26
- Technical
- Relative Strength Index (RSI)
- URGN 37.97
- SAGE 40.43
- Support Level
- URGN $11.10
- SAGE $5.03
- Resistance Level
- URGN $13.13
- SAGE $5.91
- Average True Range (ATR)
- URGN 0.53
- SAGE 0.33
- MACD
- URGN -0.10
- SAGE 0.03
- Stochastic Oscillator
- URGN 12.15
- SAGE 27.27
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About SAGE Sage Therapeutics Inc.
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.